The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya by Sudoi Raymond K et al.
RESEARCH Open Access
The magnitude and trend of artemether-
lumefantrine stock-outs at public health facilities
in Kenya
Raymond K Sudoi
1, Sophie Githinji
1, Andrew Nyandigisi
2, Alex Muturi
3, Robert W Snow
1,4 and Dejan Zurovac
1,4,5*
Abstract
Background: Health facility stock-outs of artemether-lumefantrine (AL), the common first-line therapy for
uncomplicated malaria across Africa, adversely affect effective malaria case-management. They have been
previously reported on various scales in time and space, however the magnitude of the problem and trends over
time are less clear. Here, 2010-2011 data are reported from public facilities in Kenya where alarming stock-outs
were revealed in 2008.
Methods: Data were collected between January 2010 and June 2011 as part of 18 monthly cross-sectional surveys
undertaken at nationally representative samples of public health facilities. The primary monitoring indicator was
total stock-out of all four weight-specific AL packs. The secondary indicators were stock-outs of at least one AL
pack and individual stock-outs for each AL pack. Monthly proportions and summary means of the proportions over
the monitoring period were measured for each indicator. Stock-out trends were assessed using linear regression.
Results: The number of surveyed facilities across 18 time points ranged between 162 and 176 facilities. The stock-
out means of the proportion of health facilities were 11.6% for total AL stock-out, 40.6% for stock-out of at least
one AL pack, and between 20.5% and 27.4% for stock-outs of individual AL packs. Monthly decrease of the total AL
stock-out was 0.005% (95% CI: -0.5 to +0.5; p = 0.983). Monthly decrease in the stock-out of at least one AL pack
was 0.7% (95% CI: -1.5 to +0.3; p = 0.058) while stock-outs of individual AL packs decreased monthly between 0.2%
for AL 24-pack and 0.7% for AL six-pack without statistical significance for any of the weight-specific packs.
Conclusions: Despite lower levels of AL stock-outs compared to the reports in 2008, the stock-outs at Kenyan
facilities during 2010-2011 are still substantial and of particular worry for the most detrimental:- simultaneous
absence of any AL pack. Only minor decrease was observed in the stock-outs of individual AL packs. Recently
launched interventions to eliminate AL stock-outs in Kenya are fully justified.
Background
Universal and continuous availability of artemisinin-
based combination therapy (ACT) is a critical pre-requi-
site for delivery of effective malaria case-management at
health facilities across Africa [1]. In most African coun-
tries, information on the ACT availability at peripheral
facilities is either absent or collected periodically during
the cross-sectional surveys undertaken on various scales
in time and space [2-5]. Yet, this limited information
suggests that ACT stock-outs are common, however its
trends over time are less clear. Furthermore, publicizing
ACT stock-outs is a crucial element to raise awareness
of this problem and initiate interventions aimed at elim-
ination of ACT stock-outs at the point of care [6].
In Kenya, the nationally recommended ACT, arte-
mether-lumefantrine (AL), was introduced to health facil-
ities in 2006 as the first-line treatment for uncomplicated
malaria [7]. In 2008, a cross-sectional survey undertaken
at public facilities in seven Kenyan districts revealed that a
total AL stock-out of all four weight-specific packs was
present at 26% of facilities while 75% of facilities were
stocked out of at least one AL pack [8]. In 2009, the new
National Malaria Strategy and Monitoring and Evaluation
Plan 2009-2017 was launched and specified that by 2013,
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any medium, provided the original work is properly cited.all facilities should have AL continuously in stock [9].
While the 2008 findings were alarming, it has also been
recognized that facility-based surveys undertaken periodi-
cally on limited geographical scale in nationally non-repre-
sentative districts are no longer adequate to timely
monitor national trends in the AL availability. Moreover,
although integrated within essential medicines supply,
Kenyan AL supply chain for government facilities is
further complicated by quarterly distribution of AL based
on consumption to rural health facilities in three out of
eight provinces and every two months to all hospitals
countrywide ("pull-system”), while rural facilities in the
remaining five provinces receive predetermined quantities
of AL every three months ("push-system”). In contrast to
government facilities, “pull-system” is a predominant, but
not an exclusive, distribution system for faith-based facil-
ities. Therefore, from 2010 onwards, monthly monitoring
of AL availability on the nationally representative sample
of facilities was initiated. In this brief report, the national
findings in the period between January 2010 and June
2011 are presented and the new interventions aiming to
eliminate AL stock-outs in Kenya by 2013 are highlighted.
Methods
Indicators
The indicators reflecting AL stock-out included the
stock-out of each of four weight-specific AL packs (six,
12, 18 and 24 tablets), stock-out of at least one of the
four AL packs and the total stock-out of all four AL
packs. Since the total AL stock-out is the most detri-
mental because it precludes any AL treatment at the
health facility, the primary monitoring indicator was
total AL stock-out defined ass i m u l t a n e o u sa b s e n c eo f
all four weight-specific packs on the survey day.
Sampling
The detailed explanation of the facility sampling meth-
ods is presented elsewhere [10,11]. Briefly, from the
universe of public health facilities in Kenya, a national
representativeness was assured, drawing a random
sample stratified by administrative boundaries, type of
facilities and their ownership. In each of seven sur-
veyed provinces, four strata based on the facility type
and ownership was formed. Subsequently, from each of
the 28 strata, a simple, random sample proportional to
the number of facilities in a stratum was drawn. The
estimated sample size of 170 facilities was sufficient to
obtain 95% confidence intervals of ± 7.5% around a
conservatively estimated national stock-out frequency
of 50%.
Data collection and analysis
Data were collected on a monthly basis between January
2010 and June 2011 using cross-sectional surveys
undertaken at the nationally representative sample of
public health facilities. Two rounds of physical surveys
were undertaken to assess availability of commodities
and malaria case-management practices, after which AL
stock-out data were collected through follow-up phone
call interviews with in-charges of the same facilities.
Case-management findings from physical surveys are
reported previously [11] while here AL stock-out data
combining physical and phone call surveys are reported.
The analysis was descriptive, reporting national level
estimates and included stand-alone monthly proportions
and summary means of the proportions for each indica-
tor across an 18-month monitoring period. Stock-out
trends over time were assessed for each indicator using
linear regression analysis. Analysis was undertaken in
Excel and STATA 11. Ethical approval was provided by
the Kenyatta National Hospital/University of Nairobi-
Ethics and Research Committee (KNH-ERC/A/383).
Informed written consent was obtained for all
participants.
Results
The number of surveyed facilities across 18 time points
ranged between 162 and 176 facilities. Figure 1 shows
monthly proportions and trends in stock-outs of at least
one AL pack and simultaneous stock-out of all four AL
packs (total AL stock-out). Mean of the proportion of
health facilities with total AL stock-out across the study
period was 11.6% (median 11.5%; monthly range: 3-20%)
while mean stock-out of at least one AL pack was sub-
stantially higher -40.6% (median 38.0%; monthly range:
28-59%). AL stock-outs had shown a fluctuating pattern
however overall changes in AL stock-outs during the
monitoring period were minor. Over an 18-month per-
iod, monthly decrease of total AL stock was 0.005%
(95% CI: -0.5 to +0.5; p = 0.983) while monthly decrease
in the stock-out of at least one AL pack was 0.7% (95%
CI: -1.5 to +0.3; p = 0.058).
With respect to the stock-outs of individual AL packs
over the study period, mean of the proportion of
stocked-out facilities ranged between 20.5% for AL six-
pack (median 19.4%; monthly range: 9-39%) and 27.4%
for AL 18-pack (median 26.6%; monthly range: 14-43%).
The mean stock-out of AL 12- and AL 24-packs was
respectively 27.2% (median 26.4%; monthly range: 14-
48%) and 22.4% (median 21.6%; monthly range 13-32%).
There was a minor, however statistically insignificant,
declining stock-out trend for all weight specific AL
packs during the monitoring period. Monthly decreases
were 0.7% for AL six-pack (95% CI: -1.6 to +0.1; p =
0.082), 0.5% for AL 12-pack (95% CI: -1.5% to +0.5%; p
= 0.326), 0.4% for AL 18-pack (95% CI: -1.1 to +0.3; p =
0.266) and 0.2% for AL 24-pack (95% CI: -0.3 to +0.7; p
= 0.442).
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ACT stock-out trends from a nationally representative
sample of public health facilities are reported for the
first time in Africa. The study reveals important findings
quantifying the magnitude of the problem in Kenya,
emphasizing the importance of interventions to elimi-
nate stock-outs in the country. The results of 18
months’ monitoring period in 2010-2011 revealed that
on average 12% of facilities had total AL stock-out, 41%
were missing at least one AL pack, and stock-outs of
individual weight-specific packs ranged from 21 to 27%.
On the positive side, these stock-out levels are signifi-
cantly lower than reported in 2008 when one quarter of
facilities was found without any AL and as high as three
quarters were without one or more AL packs [8]. The
stock-out indicators in each month during the 18-
month monitoring period were lower than observed in
2008 in Kenya and indeed lower than reported in several
larger and smaller cross-sectional surveys in other Afri-
can countries [2-5]. The lower levels of AL stock-outs
in the recent period are likely to be due to higher stocks
at the central level and less common procurement
delays that massively compromised AL delivery and dis-
tribution in 2008 [8,12].
Nevertheless, the levels of current AL stock-outs are
still substantial and trends do not show significant
improvements. Some fluctuations observed between
months are likely a reflection of the drug distribution
cycles with more facilities running out of stock towards
the end of the cycle. The stock-out levels are of
particular concern for the total absence of any AL pack
and the finding that over one in 10 health facilities
countrywide are unable to deliver life-saving therapy for
malaria patients is worrying. As recently observed in the
Western Kenya, the total AL stock-out has been indeed
associated with increased childhood mortality [13].
Beside the total stock-out, the stock-outs of individual
AL packs also deserve attention. Although the strength
of AL tablets is the same, four different pack sizes -
each accompanied with pictorial instructions on AL use
- are adequate for the management of four different
weight categories of patients. Improvising AL treatments
by cutting larger pack sizes for lower weight categories
or combining smaller packs for heavier patients still
enables AL dispensing however it may compromise pre-
viously observed high levels of patients’ adherence
[14,15] and treatment outcomes [16]. Indeed several
recent studies undertaken under the routine conditions
of care reported high levels of non adherence [17-20]
and the possible negative effects of the stock-outs of the
weight-specific packs on patients’ adherence merit
further investigations.
T h ei n v e s t i g a t i o n so ft h ec a u s e so fA Ls t o c k - o u t sa r e
beyond the scope of this monitoring exercise and quali-
tative and quantitative studies investigating the complete
supply chain for medicines are necessary to comprehen-
sively understand these problems. Yet, acknowledging
the persistence of AL stock-outs in the country, the
Kenyan Division of Malaria Control has reinforced pro-
grammatic activities to strengthen the supply chain for
Figure 1 AL stock-out at Kenyan facilities between January 2010 and June 2011 (red bars showing total AL stock-out, blue bars
showing stock-out of at least one AL pack, and red and blue lines showing trends over time for respective stock-out indicators).
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health workers and district managers are of particular
interest. Beside the on-going activities aiming at
improvements of the routine logistic information sys-
tems through the in-service training of health workers,
supportive supervision and promoting peripheral redis-
tribution of commodities, in August 2011 a real-time
reporting of AL availability using mobile phone text-
messaging was launched in five pilot districts. The pro-
ject is following Tanzanian “SMS for Life” model which
had shown a drastic reduction of AL stock-outs by
ensuring real-time visibility of stocks that in turn
resulted in interventions mitigating stock-outs [21]. In
Kenya however, it has been recognized that causes of
AL stock-outs are not only a result of suboptimal supply
and peripheral drug management but also a conse-
quence of irrational use of anti-malarial medicines due
to low testing rates and suboptimal interpretation of test
results in clinical practice [10,11]. Therefore, to optimize
potential success of the intervention, the Kenyan “SMS
for Life” project decided to mimic Tanzanian model
with the respect to weekly reports of four AL packs but
also, alongside the scaling up process of malaria diag-
nostics, to include stock reports of rapid diagnostic tests
and basic surveillance information on testing and treat-
ment parameters. It is hoped that in the era of imperfect
drug supply the package of interventions, including
intense monitoring with high visibility at all levels of
care and adequate local responses, may be sufficient to
enable Kenya to eliminate stock-outs and achieve 2013
targets of universal and continuous AL availability.
Furthermore, if this impact could be obtained through
real-time reporting on the national scale there will be
obviously a reduced need for repeated national surveys
to monitor trends. Finally, it should be acknowledged
that interventions at district levels such as these initiated
in Kenya, have potential only if major stock-outs at the
central level do not occur. Fortunately, this potential,
higher level problem of the supply chain, despite some
deficiencies that are beyond the scope of this report, has
not been encountered recently on a major scale in
Kenya.
Conclusions
Lower levels of AL stock-outs during 18 months of
monitoring period in 2010-2011 were found than pre-
viously reported in Kenya. However, 2010-2011 stock-
out levels are still substantial and without significant
improvements over time. In Kenya, as well as in other
African countries, monitoring and reporting of ACT
stock-outs should be a regular activity, important to
inform national policies and donors on the progress in
the implementation of anti-malarial drug policies but
also to raise awareness and initiate interventions to
potentially mitigate this problem.
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